Health Canada approves Novo Nordisk’s Wegovy to cut heart attacks
Health Canada has approved Novo Nordisk’s semaglutide injection, Wegovy, marking it as the first treatment in the country authorised to…
Cardiovascular
-
-
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat…
-
AHA 2024: lerodalcibep shows promising results in open-label extension trial in HeFH patients
On November 16, at the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, IL, US, clinical trial results…
-
Lexicon partners Viatris for global expansion of sotagliflozin
Lexicon Pharmaceuticals has entered a licensing agreement with Viatris, granting the latter exclusive rights to commercialise sotagliflozin in all indications…
-
ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy
The results of two subanalyses of the PACMAN-AMI trial were presented on the final day (2 September) of the European…
-
ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy
On 31 August, at this year’s European Society of Cardiology (ESC) conference, during a late-breaking science session on the topic…
-
ESC 2024: Study highlights potential for Novartis to differentiate in HF space
On 30 August, at this year’s European Society of Cardiology (ESC) conference, during a late-breaking science session on the topic…
-
Flagship, Quotient and Pfizer link on cardiovascular and renal disease
Flagship Pioneering and Quotient Therapeutics have entered a strategic partnership with Pfizer to identify new therapeutic targets for cardiovascular and…
-
US judge denies initial attempt by Novartis to block generic Entresto launch
Novartis’s bid to block the launch of a biosimilar for its best-selling drug Entresto (sacubitril/valsartan) got off to a faltering…
-
Bayer set to expand Kerendia’s label in cardiology with Phase III win
Bayer is looking to expand the use of Kerendia (finerenone) beyond type 2 diabetes (T2D), as the therapy showed efficacy…
